Artelo Biosciences
ARTL
3 hedge funds and large institutions have $36.6K invested in Artelo Biosciences in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
43% more capital invested
Capital invested by funds: $25.6K → $36.6K (+$10.9K)
0.37% more ownership
Funds ownership: 0.7% → 1.07% (+0.37%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.45K |
ARTL Hedge Fund Activity: Q4 2024 in Review
3 of the 7,608 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q4 2024, worth a combined $36.6K — up 43% from $25.6K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ARTL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $14.8K. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.45K.
- 3 institutional investors held Artelo Biosciences (ARTL) as of Q4 2024, up from 2 in Q3 2024.
- Funds reported $36.6K of Artelo Biosciences stock for Q4 2024, up 43% quarter-over-quarter.
- 1 fund opened new Artelo Biosciences positions in Q4 2024 and 0 closed out, a net change of +1 holder.
- The largest Artelo Biosciences buyer in Q4 2024 was UBS Group, an estimated $14.8K added.
- The largest Artelo Biosciences seller in Q4 2024 was Tower Research Capital (TRC), an estimated $1.45K sold.
Based on aggregated 13F filings for Q4 2024.